Acute lymphoblastic leukemia (ALL) is the most common form of cancer in children. Survival rates for ALL have improved dramatically during the past 20 years. The goals of the current trials are to further improve clinical outcome and to minimize side effects.
Methotrexate (MTX) is one of the drugs used in the treatment of childhood ALL. MTX acts by inhibiting two enzymes. First, as an analog of folate, MTX is a powerful competitive inhibitor (1000-fold more potent than the natural substrate) of dihydrofolate reductase ( Figure 1 ). Dihydrofolate reductase is responsible for converting folates to their active form tetrahydrofolate, which is a substrate of thymidylate synthase (TS). Second, the polyglutamated forms of MTX inhibit TS directly. Due to this inhibition, the cells will not be capable of de novo synthesis of purines and thymidylate and thus DNA synthesis will be inhibited.
Treatment with MTX is associated with several side effects in a considerable number of patients, although some patients do not have any side effect at all. MTX-associated mucositis, stomatitis and myelosuppression appear to be related to the folate status of the patient, especially in tissues with high cell turnover. Common polymorphisms have been described in the following folate metabolism-related genes: methionine synthase (MS 2756A4G), methylenetetrahydrofolate reductase (MTHFR 1298A4C and MTHFR 677C4T), methionine synthase reductase (MTRR 66A4G), serine hydroxymethyl transferase (SHMT1 1420C4T), reduced folate carrier (RFC1 80G4A), methylenetetrahydrofolate dehydrogenase (MTHFD1 1958G4A) and TS 28-bp tandem repeats. Figure 1 shows these enzymes to be involved in the various branches of folate metabolism.
Some of these polymorphisms have been studied in relation to the occurrence of MTX-induced side effects, but with conflicting results. Therefore, we retrospectively correlated the abovementioned polymorphisms to MTX-induced side effects in 81 children with ALL diagnosed between May 1999 and January 2003 at the Erasmus MC-Sophia Children's Hospital. The children were treated according to the Dutch Childhood Oncology Group ALL-9 protocol, which included high-dose MTX given by continuous infusion over 24 h. Three doses of leucovorin (5-formyltetrahydrofolate, 15 mg m À2 ) were given at 36, 42 and 48 h after start of MTX infusion. The patients were classified as either non-high-risk or high-risk (HR). Patients were stratified as HR if one or more of the following features were present, mediastinal mass, T-cell immunophenotype, white blood cell (WBC) countX50 Â 10 9 l À1 , central nervous system involvement, testis involvement or chromosomal translocations t(9;22) and t(4;11). Non-HR patients were treated with 2 g m À2 MTX every week for 3 weeks. HR patients were treated with four courses of 3 g m À2 every 2 weeks. MTX, prednisolone and cytosine arabinoside were giving intrathecally at the start of every MTX infusion.
Clinical data on side effects were collected objectively (blinded to genotypes) from the electronic patient files and from the patient medical files. The occurrence of side effects was studied in relation to the different genotypes. First, all patients were analyzed together, and next the non-HR and HR patients were studied separately. Toxic serum MTX levels (40.4 mmol l À1 after 48 h and 40.25 mmol l À1 after 72 h were defined as toxic, an indication for prolonged leucovorin rescue), postponement of MTX courses (WBCo2 Â 10 9 l À1 , platelet count o75 Â 10 9 l À1 , mucositis and/or clinical infection at the day the new course was scheduled), oral mucositis, hospital admission (because of pain, mucositis or dehydration), blood transfusion (indication: hemoglobin o4.3 mmol l À1 or when clinically necessary), hepatic (transaminase levels 42 times normal limit) and skin toxicity were represented by the values 0 or 1, indicating whether an event did (at least once) or did not occur during the MTX courses. The difference in hemoglobin, WBC and the platelet values after the second MTX course (defined as the difference between the time points '1 week after' for the non-high-risk patients and '2 weeks after' for the HR patients and the 'start' of the second MTX course) were evaluated as continuous variables. (Due to incompleteness of data, the WBC and thrombocyte decline could only be evaluated following the second MTX course.) Hematological toxicity was also graded according to the NCI Common Terminology Criteria for Adverse Events (NCIFCTCAE v3.0).
For genotype analysis, we used cytospins involving 25 Â 10 3 leukemic cells, stored at À20 1C. To isolate DNA, bleached cotton was sterilized in an autoclave and cut into small pieces (0.5 Â 0.5 cm). The pieces of cotton were first pre-wetted with H 2 O. Under sterile conditions the leukemic blasts were then isolated by wiping the slides with the wetted cotton using forceps. Here, the blasts became attached to the cotton. To be sure as many blasts as possible were taken off the slide, a second piece of cotton was then used in an identical way. The two pieces of cotton were put in an Eppendorf vial and 200 ml phosphate-buffered saline was added, and genomic DNA was isolated. The presence of MS 2756A4G, MTHFR 1298A4C, MTHFR 677C4T, SHMT1 1420C4T, RFC1 80G4A and MTHFD1 1958G4A polymorphisms was determined using the PCR-restriction fragment length polymorphism method as described before. 1 Double (2R2R) or triple (3R3R) 28-bp tandem repeats in the promoter region of TS were visualized on agarose gel directly after the PCR reaction. The MTRR 66A4G polymorphism was determined using a real-time PCR. 1 The genotype distribution as found in our 81 patients is depicted in the Table 1 . Genotyping was not successful in two cases for MTRR and in one case for SHMT1, RFC1 and MTHFD1.
Methotrexate-related side effects were studied in relation to the different polymorphisms. The MTHFR 1298A4C polymorphism was significantly correlated with the number of blood transfusions during the MTX courses; 50% of the patients with the AA genotype required red blood cell transfusions as compared with 24 and 20% of the patients with the AC and CC genotypes (Table 1 , P ¼ 0.043). Median WBC count increased after MTX course II among HR patients, for patients with MTHFR 1298 AC and CC genotypes ( þ 0.51 Â 10 9 l À1 , n ¼ 10), whereas WBC count decreased for the wild type, AA genotype (À0.41 Â 10 9 l À1 , n ¼ 21, P ¼ 0.053; Figure 2 ). However, this decreasing WBC count in the MTHFR 1298 wild-type patients did not lead to a higher NCI toxicity grade. Thus, the MTHFR 1298 AC/CC genotypes were associated with a decrease in hematological toxicity (more than twofold less blood transfusions and a more rapid recovery of leukocyte count in HR ALL patients). MTHFR acts as a critical enzyme in folate metabolism by catalyzing the irreversible conversion of 5,10-methylenetetrahydrofolate (methyl-donor for dTMP synthesis) to 5-methyltetrahydrofolate, a carbon-donor for methionine synthesis. The 1298 A4C polymorphism results in a glutamate-to-alanine change and diminished enzyme activity. Reduced conversion of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate may lead to more substrate for TS and thereby to more DNA synthesis, which might result in lesser side effects. However, it might result in less antileukemic activity as well. (Figure 1 ) Alternatively, reduced conversion of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate may lead to inhibition of methylation reactions (hypomethylation), which has been associated with MTX toxicity. In a recent study, we showed that the MTHFR 1298 AC variant was related to a decreased in vitro MTX sensitivity in children with ALL, 1 which is in line with the current results on side effects. In contrast to the present study in which patients were treated with high-dose MTX (2-3 g m À2 ), in two other studies on rheumatoid arthritis, in patients treated with low-dose MTX (o0.5 g m À2 ), the MTHFR 1298 C allele was found to be associated with increased toxicity and better disease control. Studies on MTHFR 677 C4T polymorphism, again on patients receiving low-dose MTX, showed conflicting results; some found increased toxicity in patients carrying the mutant T-allele, 2 whereas others did not Figure 1 Simplified scheme illustrating folate metabolism. DHF, dihydrofolate; DHFR, dihydrofolate reductase; dTMP, deoxythymidine-5 0 -monophosphate; dUMP, deoxyurindine-5 0 -monophosphate; MTHFR, methylenetetrahydrofolate reductase; MS, methionine synthase; MTRR, methionine synthase reductase; MTX, methotrexate; MTX-PGs, methotrexate polyglutamates; RFC, reduced folate carrier; SHMT, serine hydroxymethyl transferase; THF, tetrahydrofolate; TS, thymidylate synthase.
Figure 2
Association between MTHFR 1298A4C and WBC count recovery. The differences in WBC and the platelet values between the time points 2 weeks after and the beginning of the second MTX course were evaluated. The MTHFR 1298 AC and CC genotypes (n ¼ 10) are correlated to an increase in WBC after the MTX course in high risk ALL patients (n ¼ 31), whereas WBC count decreases in wild-type patients. The box depicts the median and the P25-P75 interval. ALL, acute lymphoblastic leukemia; MTHFR, methylenetetrahydrofolate reductase; MTX, methotrexate; WBC, white blood cell. Letters to the Editor find any such relationship and one study even reported lower toxicity in carriers of the mutant T-allele in pediatric ALL patients receiving low-dose MTX. 3 Contrasting these studies of low-dose MTX regimens, in the present study and in two recent studies on non-Hodgkin's lymphoma and ALL patients 4,5 using a high-dose MTX containing treatment protocol, no association was found between MTHFR 677C4T and MTX-induced side effects. Another recent study of 240 pediatric ALL patients receiving both low-and high-dose MTX did not show any relationship between MTHFR 677C4T or MTHFR 1298 A4C polymorphisms and MTX-induced toxicity. 6 This study reported an association between RFC 80 G4A polymorphism and gastrointestinal toxicity upon high-and low-dose MTX treatment, 6 which is in contrast to our findings. The conflicting results between studies describing patients treated with low-or high-dose MTX suggest that MTX dosage may influence the genotype-related effect on MTX-related side effects. However, discrepancies between the different studies relating gene polymorphisms and toxicity might also be explained by environmental factors like folate status, diet and concurrent medications, as suggested by Krajinovic et al. 7 In the current study, significantly more patients with an MTRR AG or GG genotype experienced oral mucositis as compared with patients with the wild-type genotype (P ¼ 0.018) ( Table 1 ). The function of the MTRR enzyme is to maintain adequate levels of methylcobalamin, the activated cofactor for methionine synthase, which catalyzes the remethylation of homocysteine to methionine. Polymorphisms in the MTRR gene could change the enzyme activity and result in rearrangements of folate distribution (Figure 1) . Because the exact effect of MTRR polymorphisms on enzyme activity is not known, the cause of the association with increased MTX-induced side effects remains speculative. In contrast to the data on increased frequency of mucositis, we found that HR patients carrying the MTRR 66 AG variant showed a faster platelet recovery than the MTRR 66 AA (wt) and MTRR 66 GG genotypes (P ¼ 0.004) (data not shown), although this was not reflected in a lower NCI toxicity grade. However, we doubt the clinical relevance of this latter finding, since the relation was shown only for the heterozygous genotype. In a previous study, we showed that the MTRR 66 G-allele was associated with decreased in vitro MTX sensitivity in leukemic cells from children with ALL.
1 This contrasts our current findings on MTX toxicity and we conclude that this warrants further research, both the correlation between the MTRR 66 polymorphism and cytotoxicity in the leukemic cells and the occurrence of side effects, as well as functional studies on whether these polymorphisms change the enzyme activity.
In our cohort, the patients with the SHMT 1420 CT genotype showed less frequent elevations of serum transaminases (thus less hepatotoxicity) along the MTX courses, compared with the CC and TT genotypes (P ¼ 0.036; Table 1 ). SHMT catalyzes the reversible conversion of serine and tetrahydrofolate to glycine and 5,10-methylenetetrahydrofolate. Again, the clinical relevance is questionable, since the wild type and the homozygous polymorphic genotypes did not show differences according to hepatotoxicity. However, the results are in line with our previous study in which we showed that the SHMT 1420 TT variant was related to decreased in vitro cytotoxicity in leukemic cells of children with ALL. 1 No significant correlations were observed between MTXrelated side effects and MS 2756A4G, MTHFR 677C4T, TS 2R3R tandem repeats, RFC 80G4A and MTHFD1 1958G4A genotypes.
Since this was a retrospective study with only a relatively low number of included patients, and since other studies on pediatric ALL patients showed conflicting results, our conclusions need confirmation in a prospective study including higher patient numbers. Such a study is currently being performed, allowing correction for multiple testing and multivariate analysis, including variables like age, sex, leucovorin rescue or toxic MTX levels.
In conclusion, in this retrospective study with a limited number of 81 childhood ALL patients, we analyzed the relationship between polymorphisms in a series of folate-related genes and side effects of high-dose MTX treatment. The MTHFR 1298 AC and CC and SHMT 1420 CT genotypes appeared to be correlated with less toxicity, and the MTRR 66 AG and GG genotypes were correlated to an increased occurrence of MTXinduced toxicity. 
